Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Matthew Fury, M.D.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Segal NH, Ou SI, Balmanoukian A, Fury MG, Massarelli E, Brahmer JR, Weiss J, Schöffski P, Antonia SJ, Massard C, Zandberg DP, Khleif SN, Xiao F, Rebelatto MC, Steele KE, Robbins PB, Angra N, Song X, Abdullah S, Butler M. Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort. Eur J Cancer. 2019 03; 109:154-161. PMID: 30731276.
    Citations: 25     Fields:    Translation:HumansCTClinical Trials
  2. Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 07 26; 379(4):341-351. PMID: 29863979.
    Citations: 284     Fields:    Translation:HumansCTClinical Trials
  3. Papadopoulos KP, Romero RS, Gonzalez G, Dix JE, Lowy I, Fury M. Anti-Hu-Associated Autoimmune Limbic Encephalitis in a Patient with PD-1 Inhibitor-Responsive Myxoid Chondrosarcoma. Oncologist. 2018 01; 23(1):118-120. PMID: 29158368.
    Citations: 20     Fields:    Translation:Humans
  4. Dunn LA, Fury MG, Sherman EJ, Ho AA, Katabi N, Haque SS, Pfister DG. Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer. Head Neck. 2018 02; 40(2):233-241. PMID: 28963790.
    Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
  5. Sherman EJ, Dunn LA, Ho AL, Baxi SS, Ghossein RA, Fury MG, Haque S, Sima CS, Cullen G, Fagin JA, Pfister DG. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer. Cancer. 2017 Nov 01; 123(21):4114-4121. PMID: 28662274.
    Citations: 23     Fields:    Translation:HumansCTClinical Trials
  6. Soumerai JD, Zelenetz AD, Moskowitz CH, Palomba ML, Hamlin PA, Noy A, Straus DJ, Moskowitz AJ, Younes A, Matasar MJ, Horwitz SM, Portlock CS, Konner JA, Gounder MM, Hyman DM, Voss MH, Fury MG, Gajria D, Carvajal RD, Ho AL, Beumer JH, Kiesel B, Zhang Z, Chen A, Little RF, Jarjies C, Dang TO, France F, Mishra N, Gerecitano JF. The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. Clin Cancer Res. 2017 Aug 01; 23(15):4119-4126. PMID: 28314788.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  7. Smyth LM, Monson KR, Jhaveri K, Drilon A, Li BT, Abida W, Iyer G, Gerecitano JF, Gounder M, Harding JJ, Voss MH, Makker V, Ho AL, Razavi P, Iasonos A, Bialer P, Lacouture ME, Teitcher JB, Erinjeri JP, Katabi N, Fury MG, Hyman DM. A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. Invest New Drugs. 2017 12; 35(6):742-750. PMID: 28281183.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  8. Falchook GS, Leidner R, Stankevich E, Piening B, Bifulco C, Lowy I, Fury MG. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. J Immunother Cancer. 2016; 4:70. PMID: 27879972.
    Citations: 42     Fields:    Translation:Humans
  9. Russo R, Fury M, Accardo S, Krause P. Economic and Educational Impact of Firearm-Related Injury on an Urban Trauma Center. Orthopedics. 2016 Jan-Feb; 39(1):e57-61. PMID: 26730690.
    Citations: 4     Fields:    Translation:Humans
  10. Fury MG, Xiao H, Sherman EJ, Baxi S, Smith-Marrone S, Schupak K, Gewanter R, Gelblum D, Haque S, Schoder H, Shah JP, Katabi N, Kurtzman R, Lipson B, Cox L, Lee NY, Pfister DG. Phase II trial of bevacizumab?+?cetuximab?+?cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma. Head Neck. 2016 04; 38 Suppl 1:E566-70. PMID: 25784616.
    Citations: 15     Fields:    Translation:HumansCTClinical Trials
  11. Scher ED, Romesser PB, Chen C, Ho F, Wuu Y, Sherman EJ, Fury MG, Wong RJ, McBride S, Lee NY, Riaz N. Definitive chemoradiation for primary oral cavity carcinoma: A single institution experience. Oral Oncol. 2015 Jul; 51(7):709-15. PMID: 25958830.
    Citations: 11     Fields:    Translation:HumansPHPublic Health
  12. Pfister DG, Baxi SS, Dunn LA, Fury MG. Reply to B. O'Sullivan et Al. J Clin Oncol. 2015 May 20; 33(15):1710. PMID: 25823736.
    Citations: 1     Fields:    Translation:HumansCells
  13. Hyman DM, Snyder AE, Carvajal RD, Gerecitano JF, Voss MH, Ho AL, Konner J, Winkelmann JL, Stasi MA, Monson KR, Iasonos A, Spriggs DR, Bialer P, Lacouture ME, Teitcher JB, Katabi N, Fury MG. Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. Cancer Chemother Pharmacol. 2015 Apr; 75(4):747-55. PMID: 25672916.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  14. Pfister DG, Fury MG. New chapter in our understanding of human papillomavirus-related head and neck cancer. J Clin Oncol. 2014 Oct 20; 32(30):3349-52. PMID: 25225434.
    Citations: 8     Fields:    Translation:HumansCells
  15. Shapiro LQ, Sherman EJ, Riaz N, Setton J, Koutcher L, Zhang Z, Shi W, Fury MG, Wolden SL, Pfister DG, Morris L, Lee N. Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC). Oral Oncol. 2014 Oct; 50(10):947-55. PMID: 25132089.
    Citations: 17     Fields:    Translation:Humans
  16. Riaz N, Hong JC, Sherman EJ, Morris L, Fury M, Ganly I, Wang TJ, Shi W, Wolden SL, Jackson A, Wong RJ, Zhang Z, Rao SD, Lee NY. A nomogram to predict loco-regional control after re-irradiation for head and neck cancer. Radiother Oncol. 2014 Jun; 111(3):382-7. PMID: 24993329.
    Citations: 25     Fields:    Translation:Humans
  17. Ho AL, Lipson BL, Sherman EJ, Xiao H, Fury MG, Apollo A, Seetharamu N, Sima CS, Haque S, Lyo JK, Sales R, Cox L, Pfister DG. A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer. Invest New Drugs. 2014 Jun; 32(3):549-54. PMID: 24566705.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  18. Iyengar NM, Kochhar A, Morris PG, Morris LG, Zhou XK, Ghossein RA, Pino A, Fury MG, Pfister DG, Patel SG, Boyle JO, Hudis CA, Dannenberg AJ. Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue. Cancer. 2014 Apr 01; 120(7):983-91. PMID: 24449483.
    Citations: 21     Fields:    Translation:Humans
  19. Fury MG, Lee NY, Sherman E, Ho AL, Rao S, Heguy A, Shen R, Korte S, Lisa D, Ganly I, Patel S, Wong RJ, Shaha A, Shah J, Haque S, Katabi N, Pfister DG. A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2013 Nov 01; 87(3):479-86. PMID: 24074921.
    Citations: 17     Fields:    Translation:HumansCTClinical Trials
  20. Chaft JE, Rusch V, Ginsberg MS, Paik PK, Finley DJ, Kris MG, Price KA, Azzoli CG, Fury MG, Riely GJ, Krug LM, Downey RJ, Bains MS, Sima CS, Rizk N, Travis WD, Rizvi NA. Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers. J Thorac Oncol. 2013 Aug; 8(8):1084-90. PMID: 23857398.
    Citations: 41     Fields:    Translation:HumansCTClinical Trials
  21. Hellmann MD, Chaft JE, Rusch V, Ginsberg MS, Finley DJ, Kris MG, Price KA, Azzoli CG, Fury MG, Riely GJ, Krug LM, Downey RJ, Bains MS, Sima CS, Rizk N, Travis WD, Rizvi NA, Paik PK. Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab. Cancer Chemother Pharmacol. 2013 Aug; 72(2):453-61. PMID: 23811982.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  22. Sherman EJ, Su YB, Lyall A, Schöder H, Fury MG, Ghossein RA, Haque S, Lisa D, Shaha AR, Tuttle RM, Pfister DG. Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma. Thyroid. 2013 May; 23(5):593-9. PMID: 23186033.
    Citations: 34     Fields:    Translation:HumansCTClinical Trials
  23. Fury MG, Sherman E, Ho AL, Xiao H, Tsai F, Nwankwo O, Sima C, Heguy A, Katabi N, Haque S, Pfister DG. A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer. Cancer. 2013 May 15; 119(10):1823-31. PMID: 23408298.
    Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
  24. Riaz N, Sherman EJ, Fury M, Lee N. Should cetuximab replace Cisplatin for definitive chemoradiotherapy in locally advanced head and neck cancer? J Clin Oncol. 2013 Jan 10; 31(2):287-8. PMID: 23213096.
    Citations: 7     Fields:    Translation:Humans
  25. Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan SK, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Haque S, Pfister DG. A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw. 2012 Nov 01; 10(11):1391-8. PMID: 23138167.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  26. Lim R, Eaton A, Lee NY, Setton J, Ohri N, Rao S, Wong R, Fury M, Schöder H. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med. 2012 Oct; 53(10):1506-13. PMID: 22895812.
    Citations: 66     Fields:    Translation:HumansCells
  27. Rao SD, Fury MG, Pfister DG. Molecular-targeted therapies in head and neck cancer. Semin Radiat Oncol. 2012 Jul; 22(3):207-13. PMID: 22687945.
    Citations: 5     Fields:    Translation:Humans
  28. Baxi S, Fury M, Ganly I, Rao S, Pfister DG. Ten years of progress in head and neck cancers. J Natl Compr Canc Netw. 2012 Jul 01; 10(7):806-10. PMID: 22773796.
    Citations: 18     Fields:    Translation:Humans
  29. Fury MG, Sherman E, Ho A, Katabi N, Sima C, Kelly KW, Nwankwo O, Haque S, Pfister DG. A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC). Cancer Chemother Pharmacol. 2012 Jul; 70(1):121-8. PMID: 22644799.
    Citations: 17     Fields:    Translation:HumansCTClinical Trials
  30. Fury MG, Lee NY, Sherman E, Lisa D, Kelly K, Lipson B, Carlson D, Stambuk H, Haque S, Shen R, Kraus D, Shah J, Pfister DG. A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer. Cancer. 2012 Oct 15; 118(20):5008-14. PMID: 22415650.
    Citations: 29     Fields:    Translation:HumansCTClinical Trials
  31. Thiagarajan A, Caria N, Schöder H, Iyer NG, Wolden S, Wong RJ, Sherman E, Fury MG, Lee N. Target volume delineation in oropharyngeal cancer: impact of PET, MRI, and physical examination. Int J Radiat Oncol Biol Phys. 2012 May 01; 83(1):220-7. PMID: 22035663.
    Citations: 19     Fields:    Translation:Humans
  32. Sherman EJ, Lim SH, Ho AL, Ghossein RA, Fury MG, Shaha AR, Rivera M, Lin O, Wolden S, Lee NY, Pfister DG. Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review. Radiother Oncol. 2011 Dec; 101(3):425-30. PMID: 21981877.
    Citations: 38     Fields:    Translation:Humans
  33. Fury MG, Sherman E, Haque S, Korte S, Lisa D, Shen R, Wu N, Pfister D. A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012 Mar; 69(3):591-8. PMID: 21913034.
    Citations: 24     Fields:    Translation:HumansCTClinical Trials
  34. Lok BH, Setton J, Caria N, Romanyshyn J, Wolden SL, Zelefsky MJ, Park J, Rowan N, Sherman EJ, Fury MG, Ho A, Pfister DG, Wong RJ, Shah JP, Kraus DH, Zhang Z, Schupak KD, Gelblum DY, Rao SD, Lee NY. Intensity-modulated radiation therapy in oropharyngeal carcinoma: effect of tumor volume on clinical outcomes. Int J Radiat Oncol Biol Phys. 2012 Apr 01; 82(5):1851-7. PMID: 21640497.
    Citations: 23     Fields:    Translation:Humans
  35. Fury MG, Pfister DG. Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw. 2011 Jun 01; 9(6):681-9. PMID: 21636539.
    Citations: 8     Fields:    Translation:Humans
  36. Shukla-Dave A, Lee NY, Jansen JF, Thaler HT, Stambuk HE, Fury MG, Patel SG, Moreira AL, Sherman E, Karimi S, Wang Y, Kraus D, Shah JP, Pfister DG, Koutcher JA. Dynamic contrast-enhanced magnetic resonance imaging as a predictor of outcome in head-and-neck squamous cell carcinoma patients with nodal metastases. Int J Radiat Oncol Biol Phys. 2012 Apr 01; 82(5):1837-44. PMID: 21601373.
    Citations: 58     Fields:    Translation:Humans
  37. Jansen JF, Schöder H, Lee NY, Stambuk HE, Wang Y, Fury MG, Patel SG, Pfister DG, Shah JP, Koutcher JA, Shukla-Dave A. Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):299-307. PMID: 21236594.
    Citations: 49     Fields:    Translation:HumansCells
  38. Fury MG, Baxi S, Shen R, Kelly KW, Lipson BL, Carlson D, Stambuk H, Haque S, Pfister DG. Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Anticancer Res. 2011 Jan; 31(1):249-53. PMID: 21273606.
    Citations: 46     Fields:    Translation:HumansCTClinical Trials
  39. Setton J, Caria N, Romanyshyn J, Koutcher L, Wolden SL, Zelefsky MJ, Rowan N, Sherman EJ, Fury MG, Pfister DG, Wong RJ, Shah JP, Kraus DH, Shi W, Zhang Z, Schupak KD, Gelblum DY, Rao SD, Lee NY. Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):291-8. PMID: 21167652.
    Citations: 58     Fields:    Translation:Humans
  40. Laurie SA, Ho AL, Fury MG, Sherman E, Pfister DG. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol. 2011 Aug; 12(8):815-24. PMID: 21147032.
    Citations: 106     Fields:    Translation:Humans
  41. Fury MG, Drobnjak M, Sima CS, Asher M, Shah J, Lee N, Carlson D, Wendel HG, Pfister DG. Tissue microarray evidence of association between p16 and phosphorylated eIF4E in tonsillar squamous cell carcinoma. Head Neck. 2011 Sep; 33(9):1340-5. PMID: 21837706.
    Citations: 8     Fields:    Translation:HumansCells
  42. Koutcher L, Sherman E, Fury M, Wolden S, Zhang Z, Mo Q, Stewart L, Schupak K, Gelblum D, Wong R, Kraus D, Shah J, Zelefsky M, Pfister D, Lee N. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):915-22. PMID: 20947269.
    Citations: 63     Fields:    Translation:Humans
  43. Fury MG, Haque S, Stambuk H, Shen R, Carlson D, Pfister D. A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer. Cancer. 2011 Feb 15; 117(4):795-801. PMID: 20922785.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  44. Fury MG, Shah JP. Induction chemotherapy in the management of head and neck cancer. J Surg Oncol. 2010 Mar 15; 101(4):292-8. PMID: 20187068.
    Citations: 5     Fields:    Translation:Humans
  45. Jansen JF, Schöder H, Lee NY, Wang Y, Pfister DG, Fury MG, Stambuk HE, Humm JL, Koutcher JA, Shukla-Dave A. Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases. Int J Radiat Oncol Biol Phys. 2010 Aug 01; 77(5):1403-10. PMID: 19906496.
    Citations: 41     Fields:    Translation:Humans
  46. Schöder H, Fury M, Lee N, Kraus D. PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med. 2009 May; 50 Suppl 1:74S-88S. PMID: 19380408.
    Citations: 51     Fields:    Translation:Humans
  47. Lee N, Nehmeh S, Schöder H, Fury M, Chan K, Ling CC, Humm J. Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009 Sep 01; 75(1):101-8. PMID: 19203843.
    Citations: 37     Fields:    Translation:Humans
  48. Hensley ML, Larkin J, Fury M, Gerst S, Tai DF, Sabbatini P, Konner J, Orlando M, Goss TL, Aghajanian CA. A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer. Clin Cancer Res. 2008 Oct 01; 14(19):6310-6. PMID: 18829514.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  49. Figlin RA, Brown E, Armstrong AJ, Akerley W, Benson AB, Burstein HJ, Ettinger DS, Febbo PG, Fury MG, Hudes GR, Kies MS, Kwak EL, Morgan RJ, Mortimer J, Reckamp K, Venook AP, Worden F, Yen Y. NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw. 2008 Sep; 6 Suppl 5:S1-20; quiz S21-2. PMID: 18926092.
    Citations: 16     Fields:    Translation:HumansCells
  50. Ong SC, Schöder H, Lee NY, Patel SG, Carlson D, Fury M, Pfister DG, Shah JP, Larson SM, Kraus DH. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer. J Nucl Med. 2008 Apr; 49(4):532-40. PMID: 18344440.
    Citations: 66     Fields:    Translation:Humans
  51. Fury MG, Lipton A, Smith KM, Winston CB, Pfister DG. A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors. Cancer Immunol Immunother. 2008 Feb; 57(2):155-63. PMID: 17602224.
    Citations: 26     Fields:    Translation:HumansCTClinical Trials
  52. Fury MG, Zahalsky A, Wong R, Venkatraman E, Lis E, Hann L, Aliff T, Gerald W, Fleisher M, Pfister DG. A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest New Drugs. 2007 Apr; 25(2):165-72. PMID: 16983506.
    Citations: 24     Fields:    Translation:HumansCTClinical Trials
  53. Fury MG, Solit DB, Su YB, Rosen N, Sirotnak FM, Smith RP, Azzoli CG, Gomez JE, Miller VA, Kris MG, Pizzo BA, Henry R, Pfister DG, Rizvi NA. A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2007 Mar; 59(4):467-75. PMID: 16896930.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  54. Fury MG, Krug LM, Azzoli CG, Sharma S, Kemeny N, Wu N, Kris MG, Rizvi NA. A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2006 May; 57(5):671-7. PMID: 16136310.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  55. Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 2005 May-Jun; 11(3):241-7. PMID: 16053668.
    Citations: 135     Fields:    Translation:Humans
  56. Park SM, Liu G, Kubal A, Fury M, Cao L, Marx SO. Direct interaction between BKCa potassium channel and microtubule-associated protein 1A. FEBS Lett. 2004 Jul 16; 570(1-3):143-8. PMID: 15251455.
    Citations: 17     Fields:    Translation:AnimalsCells
  57. Fury M, Marx SO, Marks AR. Molecular BKology: the study of splicing and dicing. Sci STKE. 2002 Mar 12; 2002(123):pe12. PMID: 11891347.
    Citations: 16     Fields:    Translation:HumansAnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Fury's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (247)
Co-Authors (3)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.